COLORECTAL CANCER (CRC)
3rd most commonly diagnosed cancer worldwide
1,849,518 new cases in 2018 worldwide
2nd most lethal cancer worldwide
880,792 deaths in 2018 worldwide
67% of treated patients survive 5 years or more
CLINICAL PATH
Preclinical POC validation (ongoing)
Dossier preparation for submission of Pre-IND meeting request with FDA
SYNERGISTIC INTERACTION OF RCC-33 ON COLON CANCER CELL LINES
RCC-33: >70% dead cancer cells
CANNABICS™ RCC-33 DRUG CANDIDATE FOR TREATING COLON CANCER
A novel cannabinoid-based formulation
Formula demonstrated significant synergistic antitumor effect in pre clinical studies
No psychoactive effect
Patent pending
Comments